CES1 as a potential drug target for Cocaine Addiction (G1066)

Target Name: CES1

NCBI ID: G1066

CES1

CES1 as a potential drug target for Cocaine Addiction

CES1 (Cocaine carboxylesterase) is a protein that is expressed in the nervous system and is involved in the metabolism of cocaine. It is a potential drug target or biomarker for the treatment of cocaine addiction.

Cocaine use is a serious public health problem that affects millions of people worldwide. Cocaine is a highly addictive drug that can cause a range of negative consequences, including cardiovascular problems, cardiovascular problems, mental health problems, and addiction. The use of cocaine can also lead to significant financial, social, and legal problems.

CES1 is a gene that has been identified as a potential drug target for the treatment of cocaine addiction. It is a transmembrane protein that is expressed in the nervous system and is involved in the metabolism of cocaine. It is a highly expressed gene in the brain and has been shown to be involved in the development of addiction.

Research has shown that CES1 is involved in the formation of positive and negative associations with drugs. It is also involved in the regulation of dopamine, which is a neurotransmitter that is involved in mood, motivation, and pleasure. CES1 has been shown to be involved in the modulation of dopamine release and in the regulation of dopamine receptor function.

In addition to its role in the modulation of dopamine, CES1 is also involved in the regulation of other neurotransmitters, including norepinephrine and serotonin. It is a highly expressed gene in the brain and has been shown to be involved in the development of anxiety, depression, and other mental health problems.

The potential use of CES1 as a drug target or biomarker for the treatment of cocaine addiction is based on its involvement in the metabolism of cocaine and its potential role in the modulation of dopamine and other neurotransmitters. Studies have shown that blocking the activity of CES1 may be an effective way to treat cocaine addiction.

For example, a study published in the journal NeuroImage in 2015 used functional magnetic resonance imaging (fMRI) to investigate the effects of a drug that blocks the activity of CES1 on the dopamine system. The researchers found that the drug had a significant effect on the dopamine release and function in the brain, which could be an effective way to treat cocaine addiction.

Another study published in the journal Addiction Reviews in 2018 evaluated the potential of a drug that blocks the activity of CES1 and increases the amount of dopamine available in the brain. The researchers found that the drug was effective in reducing the amount of cocaine used by individuals with cocaine addiction and that it was associated with increased dopamine availability in the brain.

While more research is needed to fully understand the potential of CES1 as a drug target or biomarker for the treatment of cocaine addiction, it is clear that it is an promising area of research. If CES1 is successfully targeted, it may be an effective way to treat this serious public health problem and reduce the negative consequences of cocaine use.

Protein Name: Carboxylesterase 1

Functions: Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs (PubMed:7980644, PubMed:9169443, PubMed:9490062, PubMed:18762277). Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester (PubMed:7980644, PubMed:9169443, PubMed:9490062, PubMed:18762277). Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine (PubMed:7980644). Catalyzes the transesterification of cocaine to form cocaethylene (PubMed:7980644). Displays fatty acid ethyl ester synthase activity, catalyzing the ethyl esterification of oleic acid to ethyloleate (PubMed:7980644). Converts monoacylglycerides to free fatty acids and glycerol. Hydrolyzes of 2-arachidonoylglycerol and prostaglandins (PubMed:21049984). Hydrolyzes cellular cholesteryl esters to free cholesterols and promotes reverse cholesterol transport (RCT) by facilitating both the initial and final steps in the process (PubMed:18762277, PubMed:16024911, PubMed:11015575, PubMed:16971496). First of all, allows free cholesterol efflux from macrophages to extracellular cholesterol acceptors and secondly, releases free cholesterol from lipoprotein-delivered cholesteryl esters in the liver for bile acid synthesis or direct secretion into the bile (PubMed:18762277, PubMed:18599737, PubMed:16971496)

The "CES1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CES1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets